Latest News

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,

Zoom (ZM) Q4 2026 Earnings Call Transcript

The Shiller P/E ratio -- also known as the cyclically adjusted price-to-earnings (CAPE) ratio -- is flashing a rare warning sign.

The chipmaker just announced incredible quarterly results on Wednesday, and the market did nothing.

Copart (CPRT) Q3 2026 Earnings Transcript

Costco and Amazon will bounce back from the next market crash.

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

There is still plenty of upside in the AI sector despite a recent run-up.

Microsoft stock rarely trades at such low valuation levels.

Here's why Wall Street is overlooking one of the most compelling consumer goods stocks in the pet and garden industry.

The company's recent numbers were strong, and it boosted its guidance.

Chasing highly valued stocks can leave investors vulnerable to significant corrections later on.

As travel becomes more integrated into modern lifestyles, many consumers are searching for smarter ways to turn daily spending into valuable travel opportu

IonQ was mysteriously absent from the government's list, but it could still be the stock to buy in the sector.

The online giant has been running with the market lately, but its business is moving even faster.

The best investors are always thinking about ways they can upgrade their portfolios.

The cannabis industry could be on the cusp of significant growth in the coming years.

The AI-powered online insurer still has a bright future.

Huawei says it has a chipmaking breakthrough that could narrow the gap with TSMC, raising fresh questions about whether U.S. semiconductor sanctions accelerated China's push for self-sufficiency.

And no, it is not the Invesco QQQ.

Seniors hoping for a big benefit boost next year may get their wish.

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f